Patients with atherosclerotic peripheral arterial disease have a high risk of lung cancer: Systematic review and meta-analysis of literature.


Journal

Journal de medecine vasculaire
ISSN: 2542-4513
Titre abrégé: J Med Vasc
Pays: France
ID NLM: 101709200

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 23 12 2020
accepted: 23 12 2020
entrez: 23 3 2021
pubmed: 24 3 2021
medline: 8 7 2021
Statut: ppublish

Résumé

Lung cancer and atherosclerosis share common risk factors. Literature data suggest that the prevalence of lung malignancy in patients with peripheral arterial disease (PAD) is higher than in the general population. Our goal was to determine, through a systematic literature review, the prevalence of lung cancer in patients with PAD. We consulted available publications in the Cochrane library, MEDLINE, PUBMED, EMBASE, and ClinicalTrials.gov. We included all articles, written in English or French, published between 1990 and 2020 reporting the prevalence of lung cancer in patients with PAD (atherosclerotic aortic aneurysm or peripheral occlusive diseases). Patients with coronary artery disease, cardiac valvulopathy or carotid stenosis were not included. We did not include case reports. We performed a critical analysis of each article. Data were collected from two independent readers. A fixed effect model meta-analysis allowed to estimate a summary prevalence rate. We identified 303 articles, and selected 19 articles according to selection criteria. A total of 16849 patients were included (mean age 68.3 years, 75.1% of males). Aortic aneurysms were found in 29% of patients and atherosclerotic occlusive disease in 66% of patients. Lung cancer was identified in 538 patients, representing a prevalence of 3%. Lung cancer is found in 3% of patients with atherosclerotic PAD. This prevalence is higher than that found in lung cancer screening programs performed in the general population of smokers and former smokers. These patients should be screened for lung cancer. Their selection may dramatically increase the benefit of lung cancer screening.

Identifiants

pubmed: 33752847
pii: S2542-4513(20)30520-4
doi: 10.1016/j.jdmv.2020.12.005
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-65

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

F Bintein (F)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France. Electronic address: fbintein@ghpsj.fr.

A Yannoutsos (A)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France; Inserm UMR 1153 Center of Research in Epidemiology and Statistics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

G Chatellier (G)

Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

M Fontaine (M)

Université Paris XIII, Paris, France.

D Damotte (D)

Hôpital Cochin, AP-HP, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Unité Inserm U1138, centre de recherche des Cordeliers, Paris, France.

P Paterlini-Bréchot (P)

Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

G Meyer (G)

Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

V Duchatelle (V)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

V Marini (V)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

K-L Schwering (KL)

Université Paris XIII, Paris, France.

C Labrousse (C)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

H Beaussier (H)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

M Zins (M)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

S Salmeron (S)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

J-P Lajonchère (JP)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

P Priollet (P)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.

J Emmerich (J)

Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France; Inserm UMR 1153 Center of Research in Epidemiology and Statistics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

J Trédaniel (J)

Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Unité Inserm UMR-S 1124, toxicologie, pharmacologie et signalisation cellulaire, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH